Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 461 USD -1.02%
Market Cap: 118.7B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one VRTX stock under the Base Case scenario is 261.39 USD. Compared to the current market price of 461 USD, Vertex Pharmaceuticals Inc is Overvalued by 43%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VRTX Intrinsic Value
261.39 USD
Overvaluation 43%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Vertex Pharmaceuticals Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Valuation History Unavailable

Historical valuation for VRTX cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about VRTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Vertex Pharmaceuticals Inc

Provide an overview of the primary business activities
of Vertex Pharmaceuticals Inc.

What unique competitive advantages
does Vertex Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Vertex Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Vertex Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Vertex Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Vertex Pharmaceuticals Inc.

Provide P/S
for Vertex Pharmaceuticals Inc.

Provide P/E
for Vertex Pharmaceuticals Inc.

Provide P/OCF
for Vertex Pharmaceuticals Inc.

Provide P/FCFE
for Vertex Pharmaceuticals Inc.

Provide P/B
for Vertex Pharmaceuticals Inc.

Provide EV/S
for Vertex Pharmaceuticals Inc.

Provide EV/GP
for Vertex Pharmaceuticals Inc.

Provide EV/EBITDA
for Vertex Pharmaceuticals Inc.

Provide EV/EBIT
for Vertex Pharmaceuticals Inc.

Provide EV/OCF
for Vertex Pharmaceuticals Inc.

Provide EV/FCFF
for Vertex Pharmaceuticals Inc.

Provide EV/IC
for Vertex Pharmaceuticals Inc.

Show me price targets
for Vertex Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Vertex Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Vertex Pharmaceuticals Inc?

What are the Net Income projections
for Vertex Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Vertex Pharmaceuticals Inc?

What are the EPS projections
for Vertex Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Vertex Pharmaceuticals Inc?

What are the EBIT projections
for Vertex Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Vertex Pharmaceuticals Inc?

Compare the revenue forecasts
for Vertex Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Vertex Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Vertex Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Vertex Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Vertex Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Vertex Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Vertex Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Vertex Pharmaceuticals Inc.

Provide ROE
for Vertex Pharmaceuticals Inc.

Provide ROA
for Vertex Pharmaceuticals Inc.

Provide ROIC
for Vertex Pharmaceuticals Inc.

Provide ROCE
for Vertex Pharmaceuticals Inc.

Provide Gross Margin
for Vertex Pharmaceuticals Inc.

Provide Operating Margin
for Vertex Pharmaceuticals Inc.

Provide Net Margin
for Vertex Pharmaceuticals Inc.

Provide FCF Margin
for Vertex Pharmaceuticals Inc.

Show all solvency ratios
for Vertex Pharmaceuticals Inc.

Provide D/E Ratio
for Vertex Pharmaceuticals Inc.

Provide D/A Ratio
for Vertex Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Vertex Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Vertex Pharmaceuticals Inc.

Provide Quick Ratio
for Vertex Pharmaceuticals Inc.

Provide Current Ratio
for Vertex Pharmaceuticals Inc.

Provide Cash Ratio
for Vertex Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Vertex Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Vertex Pharmaceuticals Inc?

What is the current Free Cash Flow
of Vertex Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Vertex Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Vertex Pharmaceuticals Inc

Current Assets 9.8B
Cash & Short-Term Investments 7.8B
Receivables 1.8B
Other Current Assets 243.7m
Non-Current Assets 12.4B
Long-Term Investments 4.8B
PP&E 2.5B
Intangibles 1.9B
Other Non-Current Assets 3.2B
Current Liabilities 4B
Accounts Payable 4B
Accrued Liabilities 3.2B
Other Current Liabilities -3.3B
Non-Current Liabilities 2.6B
Long-Term Debt 114m
Other Non-Current Liabilities 2.5B
Efficiency

Earnings Waterfall
Vertex Pharmaceuticals Inc

Revenue
10.6B USD
Cost of Revenue
-1.5B USD
Gross Profit
9.2B USD
Operating Expenses
-4.9B USD
Operating Income
4.3B USD
Other Expenses
-4.8B USD
Net Income
-479.8m USD

Free Cash Flow Analysis
Vertex Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VRTX Profitability Score
Profitability Due Diligence

Vertex Pharmaceuticals Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

Negative Free Cash Flow
Positive Gross Profit
Positive Operating Income
Exceptional 3-Year Average ROIC
62/100
Profitability
Score

Vertex Pharmaceuticals Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

VRTX Solvency Score
Solvency Due Diligence

Vertex Pharmaceuticals Inc's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

94/100
Solvency
Score

Vertex Pharmaceuticals Inc's solvency score is 94/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRTX Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRTX is 529.12 USD with a low forecast of 328.25 USD and a high forecast of 632.1 USD.

Lowest
Price Target
328.25 USD
29% Downside
Average
Price Target
529.12 USD
15% Upside
Highest
Price Target
632.1 USD
37% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VRTX?

Click here to dive deeper.

Dividends

Vertex Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VRTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VRTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VRTX News

Other Videos

Profile

Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

119.9B USD

Dividend Yield

0%

Description

Vertex Pharmaceuticals, Inc. is a global biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 3,900 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The firm's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The company offers medicines for people with serious diseases with a focus on specialty markets. The firm's four medicines are being used to treat most of the people with CF in North America, Europe and Australia.

Contact

MASSACHUSETTS
Boston
50 Northern Ave
+16173416393.0
www.vrtx.com

IPO

1991-07-24 00:00:00

Employees

3 900

Officers

Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
CEO, President & Director
Dr. Reshma Kewalramani FASN, M.D.
Executive VP & CFO
Mr. Charles F. Wagner Jr.
Executive VP & COO
Mr. Stuart A. Arbuckle B.Sc.
Executive VP & Chief Scientific Officer
Dr. David M. Altshuler M.D., Ph.D.
Senior VP & Chief Accounting Officer
Ms. Kristen C. Ambrose CPA
Show More
SVP and Chief Information & Data Officer
Mr. Mike Tirozzi
Senior Vice President of Investor Relations
Ms. Susie Lisa C.F.A.
Executive VP & Chief Legal Officer
Mr. Jonathan Biller J.D.
Senior VP & Chief Communications Officer
Ms. Nina Devlin
Show Less

See Also

Discover More
What is the Intrinsic Value of one VRTX stock?

The intrinsic value of one VRTX stock under the Base Case scenario is 261.39 USD.

Is VRTX stock undervalued or overvalued?

Compared to the current market price of 461 USD, Vertex Pharmaceuticals Inc is Overvalued by 43%.

Back to Top